Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Zhang, Ruitao ^a   Shi, Huirong ^a   Chen, Zhimin ^a   Wu, Qinghua ^a   Ren, Fang ^a   Huang, Haoliang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Metastasis associated in colon cancer 1; Ovarian carcinoma OVCAR 3 cells; Small hairpin RNA; Therapy target

Indexed keywords

CASPASE 3; CYCLIN D1; GELATINASE A; METASTASIS ASSOCIATED IN COLON CANCER 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; TUMOR MARKER; UNCLASSIFIED DRUG; MACC1 PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MESSENGER RNA; MET PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ADULT; APOPTOSIS; ARTICLE; ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NICK END LABELING; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING; ANIMAL; BAGG ALBINO MOUSE; CANCER INVASION; CELL MOTION; COLLOID CARCINOMA; CYSTADENOCARCINOMA; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ADENOCARCINOMA, MUCINOUS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; LYMPHATIC METASTASIS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 80052831073     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-83     Document Type: Article

References (24)

1. Cancer statistics, 2009. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, CA Cancer J Clin 2009 59 225 249 10.3322/caac.20006 19474385
2. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM, Nat Med 2009 15 59 67 10.1038/nm.1889 19098908
3. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Toschi L, Jänne PA, Clin Cancer Res 2008 14 5941 5946 10.1158/1078-0432.CCR-08-0071 18829470
4. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA, Science 1991 251 802 804 10.1126/science.1846706 1846706 (Pubitemid 21926175)
5. MACC1 as a marker for advanced colorectal carcinoma. Shirahata A, Shinmura K, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K, Anticancer Res 2010 30 2689 2692 20682999
6. MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K, Anticancer Res 2010 30 3441 3444 20944120
7. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, Yasumoto K, J Thorac Cardiovasc Surg 2011 141 895 898 21093878
8. MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K, Anticancer Res 2011 31 777 780 21498695
9. RNA interference by expression of short interfering RNAs and hairpin RNAs in mammalian cells. Yu JY, DeRuiter SL, Turner DL, Proc Natl Acad Sci USA 2002 99 6047 6052 10.1073/pnas.092143499 11972060 (Pubitemid 34493262)
10. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Osborne CK, Hobbs K, Clark GM, Cancer Res 1985 45 584 590 3967234 (Pubitemid 15161051)
11. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U, Int J Gynaecol Obstet 2006 95 Suppl 1 161 192 16777111
12. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW, J Natl Cancer Inst 2005 97 1407 1427 10.1093/jnci/dji289 16204691 (Pubitemid 41520077)
13. MACC1 controls Met: what a difference an Sp1 site makes. Stein U, Smith J, Walther W, Arlt F, Cell Cycle 2009 8 2467 2469 10.4161/cc.8.15.9018 19556890
14. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM, Cell 1994 77 261 271 10.1016/0092-8674(94)90318-2 7513258 (Pubitemid 24138623)
15. Unexpected domain composition of MACC1 links MET signaling and apoptosis. Kokoszyska K, Kryski J, Rychlewski L, Wyrwicz LS, Acta Biochim Pol 2009 56 317 323 19499089
16. Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Li SS, Biochem J 2005 390 641 653 16134966 (Pubitemid 41395346)
17. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Potempa S, Ridley AJ, Mol Biol Cell 1998 9 2185 2200 9693375 (Pubitemid 28373633)
18. The Met pathway: master switch and drug target in cancer progression. Mazzone M, Comoglio PM, FASEB J 2006 20 161116 161121
19. HGF/MET signaling in ovarian cancer. Zhou HY, Pon YL, Wong AS, Curr Mol Med 2008 8 469 480 10.2174/156652408785747933 18781954
20. The phosphoinositide 3-kinase pathway. Cantley LC, Science 2002 296 1655 1657 10.1126/science.296.5573.1655 12040186 (Pubitemid 34579158)
21. The MAPK signaling cascade. Seger R, Krebs EG, FASEB J 1995 9 726 735 7601337
22. Oncogenic pathways implicated in ovarian epithelial cancer. Nicosia SV, Bai W, Cheng JQ, Coppola D, Kruk PA, Hematol Oncol Clin North Am 2003 17 927 943 10.1016/S0889-8588(03)00056-X 12959183 (Pubitemid 37022149)
23. Targeting the RAF-MEK-ERK pathway in cancer therapy. Montagut C, Settleman J, Cancer Lett 2009 283 125 134 10.1016/j.canlet.2009.01.022 19217204
24. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Wu P, Hu YZ, Curr Med Chem 2010 17 4326 4341 10.2174/ 092986710793361234 20939811